1. Academic Validation
  2. Lipophilic modifications to dinucleoside polyphosphates and nucleotides that confer antagonist properties at the platelet P2Y12 receptor

Lipophilic modifications to dinucleoside polyphosphates and nucleotides that confer antagonist properties at the platelet P2Y12 receptor

  • J Med Chem. 2008 Feb 28;51(4):1007-25. doi: 10.1021/jm701348d.
James G Douglass 1 Roshni I Patel Benjamin R Yerxa Sammy R Shaver Paul S Watson Krzysztof Bednarski Robert Plourde Catherine C Redick Kurt Brubaker Arthur C Jones José L Boyer
Affiliations

Affiliation

  • 1 Departments of Chemistry, Inspire Pharmaceuticals, Inc., 4222 Emperor Boulevard, Suite 200, Durham, North Carolina 27703-8466, USA. jdouglass@inspirepharm.com
Abstract

Platelet P2Y12 receptors play a central role in the regulation of platelet function and inhibition of this receptor by treatment with drugs such as clopidogrel results in a reduction of atherothrombotic events. We discovered that modification of natural and synthetic dinucleoside polyphosphates and nucleotides with lipophilic substituents on the ribose and base conferred P2Y12 Receptor Antagonist properties to these molecules producing potent inhibitors of ADP-mediated platelet aggregation. We describe methods for the preparation of these functionalized dinucleoside polyphosphates and nucleotides and report their associated activities. By analysis of these results and by deconstruction of the necessary structural elements through selected syntheses, we prepared a series of highly functionalized nucleotides, resulting in the selection of an adenosine monophosphate derivative (62) for further clinical development.

Figures
Products